Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.84

+1.8%

Dec 19 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BulbaMan who wrote (14849)	12/21/2004 8:43:15 PM
From: IRWIN JAMES FRANKEL	Read Replies (2) of 52153

>>My guess is the next class of drugs to get hit by safety concerns is the statins. Today I was in a meeting with a room full of MD's and Phd's. The conversation turned to the Vioxx/Celebrex/Naproxin situation. The general feeling was that medical professionals would not come to the defense of these pain killers. Someone then stated that the statins were risky mentioning rapto and other risks. It was like flipping a switch. Suddenly these same medical professionals started defending the statins and the drug companies. The risks of statins were justified by the benefits of the drugs. This reaction of informed medical professionals could not be more instructive. Statins are seen as essential to health care. Pain relief is optional. ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next